-
First-Line Osimertinib for Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
What have we learned about the safety and efficacy of osimertinib for the first-line treatment of patients with EGFR-mutated advanced NSCLC?
September 13, 2023
-
Advancements of ALK Inhibition of Non-Small Cell Lung Cancer
Due to ongoing advancements, the treatment landscape for NSCLC continues to evolve. This review looks at recent developments in ALK-targeting therapies.
August 30, 2023
-
Tarlatamab: The Promising Immunotherapy on Its Way From the Lab to the Clinic
Tarlatamab shows promise as a potential targeted treatment option for small cell lung cancer, but further research is warranted.
August 21, 2023
-
Real-World Analysis of First-Line Afatinib in Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastasis
A new study looks at the effectiveness of first-line afatinib for patients with EGFR-mutated NSCLC and brain metastasis in a real-world setting.
August 07, 2023
-
Top-of-the-Art Cytometry as a Novel Tool to Aid in Lung Cancer Immunotherapy
Learn more about the exciting potential role of cytometry technologies in monitoring immunotherapy treatment responses and predicting adverse events.
July 19, 2023
-
A Promising Immunotherapy Against Small Cell Lung Cancer
This editorial provides commentary on the results from a study investigating the potential of a promising new targeted therapy for small cell lung cancer.
July 05, 2023
-
Efficacy of Different Therapies for Brain Metastases of Non-Small Cell Lung Cancer
There are a number of available treatment options for NSCLC patients with brain metastases. Which is the most effective strategy?
June 19, 2023
-
Real World Experience With Camrelizumab in Patients With Advanced Non-Small Cell Lung Cancer
A new study examines the effectiveness and safety of camrelizumab for advanced NSCLC in real-world clinical practice.
June 05, 2023
-
Strategies to Overcome Resistance to ALK Inhibitors in Non-Small Cell Lung Cancer
Certain patients with ALK-positive lung cancer may experience drug resistance to ALK-targeted therapy. What are the options?
May 22, 2023
-
Real-World Data on Severe Lung Cancer
A new study looks at real-world data on the incidence severe lung cancer and the clinical characteristics and prognosis of these patients.
May 08, 2023
-
Optimal First-Line Treatment for Metastatic ALK+ Non-Small Cell Lung Cancer
When it comes to first-line treatment options for metastatic ALK+ non-small cell lung cancer, what is the optimal choice?
April 20, 2023
-
Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Harboring BRAF Mutations
Various immune checkpoint inhibitors are used in the treatment of non-small cell lung cancer, but how effective are they in patients with BRAF mutations?
April 06, 2023
-
Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Clinical Stage III Non-Small-Cell Lung Cancer
Is this combination strategy a safe and effective treatment option for patients with resectable clinical stage III NSCLC?
March 24, 2023
-
Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients
A new study provides insight into the safety and effectiveness of camrelizumab in real world NSCLC patients with inoperable or advanced disease.
March 10, 2023
-
Preoperative Immunochemotherapy for Locally Advanced Non-Small Cell Lung Cancer
A new study evaluates the efficacy of neoadjuvant immunochemotherapy for locally advanced NSCLC in a real-world setting. What is the optimal treatment cycle?
February 21, 2023
-
Immunotherapy With Radiotherapy Fails to Improve Prognosis of Patients With Stage IV Non-Small Cell Lung Cancer
These findings suggest that stage IV NSCLC patients who receive radiotherapy in addition to immunotherapy may not realize significant improvements in prognosis.
February 07, 2023
-
Treatment Response and Safety of Immunotherapy for Advanced Non-Small Cell Lung Cancer With Comorbid Chronic Obstructive Pulmonary Disease
For advanced NSCLC patients with comorbid COPD, immunotherapy could be considered as a treatment option, but with caution.
January 16, 2023
-
Multimodal Therapy of Epithelioid Pleural Mesothelioma
This study describes a multimodal treatment approach to help improve overall survival in these patients.
January 02, 2023
-
Plasma Cell-Free DNA and Circulating Tumor Cells as Prognostic Biomarkers in Small Cell Lung Cancer Patients
A new study explores the potential prognostic value of these biomarkers in newly diagnosed small cell lung cancer patients.
December 21, 2022
-
The Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy or Anti-Angiogenic Therapy as a Second-Line or Later Treatment Option for Advanced Non-Small Cell Lung Cancer
Is immune checkpoint inhibitor combination therapy a safe and effective second-line treatment option for advanced non-small cell lung cancer patients?
December 07, 2022
